Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41951 AMERICAN HEALTHCARE REIT, INC. (Exact name of registrant as specified in its charter) | Maryland | 47-288743 ...

Financial Data and Key Metrics Changes - The company reported normalized funds from operation (FFO) of $0.46 per diluted share for Q4 2025 and $1.72 per diluted share for the full year, representing a 22% year-over-year growth in FFO per share compared to 2024 [22][23] - Total portfolio same-store NOI growth was 11.8% in Q4 and 14.2% for the full year 2025, marking the second consecutive year of double-digit growth [10][22] - The debt to EBITDA improved by nearly a full turn in 2025, indicating a stronger financial position [22][25] Business Line Data and Key Metrics Changes - The operating portfolio, including Trilogy and SHOP segments, contributed 76.9% of consolidated cash NOI, with Trilogy's same-store NOI increasing by 14% in Q4 and 18.4% for the full year [11][12] - SHOP segment same-store NOI increased by 24.6% in Q4 and 25.2% for the full year compared to the previous year [13] - Occupancy rates for Trilogy reached 90.6% in Q4, up 275 basis points year-over-year, while SHOP also surpassed 90% occupancy [12][13] Market Data and Key Metrics Changes - The company closed over $950 million in new investments in 2025, primarily in the SHOP segment, which is now the second-largest in terms of cash NOI [16][17] - The investment pipeline remains robust with over $230 million in awarded deals, indicating strong market activity [19][60] Company Strategy and Development Direction - The company maintains a disciplined investment strategy focused on high-quality care and superior health outcomes, with no changes in capital allocation or risk management frameworks [8][21] - The emphasis on high-quality care is expected to drive demand as the aging population grows, positioning the company well for future growth [12][18] - The company is actively pursuing development projects primarily focused on Trilogy expansions, aiming for attractive yields with limited market risk [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of double-digit same-store NOI growth in 2026, supported by strong occupancy levels and pricing discipline [12][13] - The leadership transition is described as seamless, with no changes in strategy, ensuring continuity in operations and execution [6][8] - The company anticipates that the demand for high-quality care will continue to grow, providing a favorable environment for its operations [12][18] Other Important Information - The company has been actively involved in off-market acquisitions, leveraging strong relationships with operators to secure favorable deals [82] - The revenue management system is being piloted with various operators, aiming to enhance pricing strategies and improve overall performance [50][51] Q&A Session Summary Question: Can you dive deeper into the acquisition environment? - The company continues to focus on higher acuity SHOP assets, which provide long-term stability [29][30] Question: Can you provide guidance on SHOP's performance? - The company expects a significant increase in pricing power as occupancy rates rise, with a conviction in future growth [35][36] Question: What are the expectations for Trilogy's occupancy and quality mix? - Trilogy's model allows for various drivers of NOI growth, with a focus on shifting to higher payor sources [39][40] Question: How is the revenue management system being rolled out? - The revenue management system is being tested with select operators, aiming to enhance their performance [50][51] Question: What is the status of the investment pipeline? - The pipeline is dynamic, with a high level of deal activity and a focus on off-market opportunities [60][61]

Financial Data and Key Metrics Changes - The company reported normalized funds from operation (NFFO) of $0.46 per diluted share for Q4 2025 and $1.72 per diluted share for the full year, representing a 22% year-over-year growth in NFFO per share [22][23] - Total portfolio same-store NOI growth was 11.8% in Q4 and 14.2% for the full year 2025, marking the second consecutive year of double-digit growth [10][22] - The debt to EBITDA improved by nearly a full turn in 2025, with a net debt to EBITDA ratio of 3.4x [22][25] Business Line Data and Key Metrics Changes - The operating portfolio, including Trilogy and SHOP segments, contributed 76.9% of consolidated cash NOI, with Trilogy's same-store NOI increasing by 14% in Q4 and 18.4% for the full year [11][12] - SHOP segment same-store NOI increased by 24.6% in Q4 and 25.2% for the full year 2025, with occupancy surpassing 90% [13][14] - Trilogy's occupancy reached 90.6% in Q4, up 275 basis points year-over-year, supported by improved quality mix and Medicare penetration [12][13] Market Data and Key Metrics Changes - The company closed over $950 million in new investments in 2025, primarily in the SHOP segment, which is now the second-largest in terms of cash NOI [16][17] - The investment pipeline remains robust, with over $230 million in awarded deals and continued deal activity expected in 2026 [19][60] Company Strategy and Development Direction - The company maintains a disciplined healthcare investment strategy focused on high-quality care and superior health outcomes, with no changes in capital allocation or risk management frameworks [8][21] - The company is prioritizing expansions in Trilogy and campus growth initiatives, aiming for attractive incremental yields with limited market risk [21] - The focus remains on relationship-driven sourcing and disciplined underwriting to ensure long-term cash flow durability and growth [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering another year of double-digit same-store NOI growth in 2026, supported by strong occupancy levels and pricing tailwinds [12][13] - The company anticipates continued demand for high-quality operators in the aging population sector, with expectations of sustained growth in the coming years [12][18] - Management highlighted the importance of maintaining operational momentum and capital availability to capitalize on growth opportunities [25][26] Other Important Information - The company has successfully accelerated several previously announced pipeline deals, closing approximately $665 million in new acquisitions in Q4 2025 [19] - The management team emphasized the importance of high-quality care and outcomes, which have contributed to strong financial performance [15][18] Q&A Session Summary Question: Can you dive deeper into the acquisition environment? - Management noted a focus on higher acuity SHOP assets, indicating confidence in long-term stability in that asset class [29] Question: Can you provide insights on SHOP guidance and occupancy? - Management acknowledged a significant occupancy increase in SHOP but indicated that future growth may not match previous years' rates [35] Question: What is the outlook for Trilogy's occupancy and quality mix? - Management highlighted the unique model of Trilogy and the importance of shifting to higher payor sources to drive NOI growth [39] Question: How does the revenue management system rollout progress? - Management confirmed that the revenue management system is being piloted with select operators, aiming to enhance overall portfolio performance [50] Question: What is the status of the investment pipeline and expected yields? - Management indicated that current acquisitions are stabilizing in the high 5% to low 6% range, with a focus on higher quality properties [67]

Financial Data and Key Metrics Changes - The company reported normalized funds from operation (FFO) of $0.46 per diluted share for Q4 2025 and $1.72 per diluted share for the full year 2025, representing a 22% year-over-year growth in FFO per share compared to 2024 [21] - Total portfolio same-store NOI growth was 11.8% in Q4 and 14.2% for the full year 2025, marking the second consecutive year of double-digit growth [10][21] - The company improved its debt to EBITDA by nearly a full turn in 2025, entering 2026 with a net debt to EBITDA ratio of 3.4 times [21][24] Business Line Data and Key Metrics Changes - The operating portfolio, including Trilogy and SHOP segments, contributed 76.9% of consolidated cash NOI, with Trilogy's same-store NOI increasing 14% in Q4 and 18.4% for the full year [11][12] - SHOP segment same-store NOI increased 24.6% in Q4 and 25.2% for the full year 2025, with occupancy surpassing 90% [13] - The company expects continued strong performance in both Trilogy and SHOP segments, with guidance for 2026 indicating 8%-12% growth in Trilogy and 15%-19% growth in SHOP [23] Market Data and Key Metrics Changes - The company closed over $950 million in new investments in 2025, primarily in the SHOP segment, which is now the second-largest in terms of cash NOI [16] - The investment pipeline includes approximately $230 million in awarded deals, with ongoing deal activity expected to increase in 2026 [19][56] - The company anticipates that competitive pressure in its markets will remain muted due to historically low levels of new supply growth [18] Company Strategy and Development Direction - The company maintains a disciplined investment and capital allocation strategy focused on high-quality care and superior health outcomes [7][8] - The strategy includes a shift towards higher acuity assets and relationship-driven sourcing for acquisitions [16][64] - The company is focused on expanding its Trilogy segment and campus growth initiatives, leveraging existing assets to mitigate market risks [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering another year of double-digit same-store NOI growth in 2026, supported by strong occupancy levels and pricing discipline [12][23] - The leadership emphasized the importance of high-quality care and health outcomes, which are expected to drive demand in the aging population [13][18] - Management acknowledged the challenges in the operating environment but remains optimistic about the company's ability to navigate these challenges and capitalize on growth opportunities [24] Other Important Information - The company has a robust pipeline of acquisitions and is prepared to deploy capital competitively in response to increasing deal activity [19][56] - The management team is committed to maintaining operational alignment and clarity of execution during the leadership transition [6][9] Q&A Session Summary Question: Can you dive deeper into the acquisition environment? - Management noted a focus on higher acuity SHOP assets, indicating confidence in long-term stability for this asset class [27] Question: Can you discuss the guidance for SHOP and potential deceleration? - Management highlighted a significant increase in occupancy in 2025 and indicated that pricing power would increase as occupancy rises [32][34] Question: What are the expectations for the investment pipeline and yields? - Management indicated that they are seeing cap rate compression and are focused on acquiring higher quality properties [63] Question: How does the revenue management system rollout progress? - Management explained that the revenue management system is being piloted with select operators, aiming to enhance performance across the portfolio [46][51] Question: What is the outlook for Trilogy investments? - Management acknowledged increased competition but emphasized their advantage in off-market acquisitions and strong relationships with operators [80][82]

Fourth Quarter 2025 Supplemental Disclaimers Forward-Looking Statements Certain statements contained in this supplemental, filed in conjunction with the Fourth Quarter 2025 Earnings Press Release, including statements relating to American Healthcare REIT, Inc.'s (the "Company") expectations regarding its performance, interest expense savings, balance sheet, net income or loss attributable to common stockholders and per diluted share, NAREIT FFO attributable to common stockholders and per diluted share, NFFO ...

Exhibit 99.1 Press Release Irvine, CA – February 26, 2026 Contact: Alan Peterson Email: investorrelations@ahcreit.com American Healthcare REIT ("AHR") Announces Fourth Quarter 2025 and Full Year 2025 Results; Issues Full Year 2026 Guidance American Healthcare REIT, Inc. (NYSE: AHR) (the "Company," "we," "our," "management," "us," or "AHR") is announcing today its fourth quarter and full year 2025 results and issuing full year 2026 guidance. Key Highlights: Page | 1 • Reported GAAP net income attributable to ...

caused by unanticipated and/or incalculable items. Definitions of the non-GAAP financial measures used herein and reconciliations to the most directly comparable financial measure calculated in accordance with GAAP can be found at the end of this earnings release. See below and "Definitions" for further information regarding the Company's non-GAAP financial measures.EBITDA and Adjusted EBITDAManagement uses earnings before interest, taxes, depreciation and amortization ("EBITDA") and Adjusted EBITDA to faci ...

American Healthcare REIT to Present at Citi 2026 Global Property CEO Conference [Accessibility Statement] Skip NavigationIRVINE, Calif., Feb. 25, 2026 /PRNewswire/ -- American Healthcare REIT, Inc. (NYSE: AHR), announced today that Chief Financial Officer, Brian S. Peay, Chief Operating Officer, Gabe M. Willhite, and VP of Investor Relations & Finance, Alan Peterson, will participate in a roundtable discussion at the Citi 2026 Global Property CEO Conference on Wednesday, March 4, 2026, from 8:10 to 8:45 a.m ...

Core Viewpoint - The article highlights a selection of five stocks that represent a diverse range of sectors including consumer, AI, infrastructure, health care, and space companies [1] Group 1: Sector Diversity - The five stocks collectively form a diverse portfolio, covering multiple industries which may appeal to a broad range of investors [1]

VANCOUVER, BC / ACCESS Newswire / February 18, 2026 / Amarc Resources Ltd. ("Amarc" or the "Company") (TSXV:AHR)(OTCQB:AXREF) is pleased to announce that it has been named to the 2026 TSX Venture 50â"¢ as one of the top 50 performing companies on the TSX Venture Exchange over the past year. ...